4-Chlorsulfonyl-zimtsaeure | 17641-30-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 4-Chlorsulfonyl-zimtsaeure
• 英文别名: 4-chlorosulfonyl-cinnamic acid；Zimtsaeure-sulfochlorid-(4)；3-(4-Chlorosulfonyl-phenyl)-acrylic acid；3-(4-chlorosulfonylphenyl)prop-2-enoic acid
• CAS: 17641-30-4
• 化学式: C₉H₇ClO₄S
• 分子量: 246.671
• InChiKey: ZGGPGWYMMZNPOY-UHFFFAOYSA-N

物化性质

• 熔点：
  >190°C (dec.)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  4-Chlorsulfonyl-zimtsaeure 在 N,N-二甲基甲酰胺 吡啶 、 草酰氯 、 盐酸羟胺 、 水 、 碳酸氢钠 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 malBel
  参考文献：
  名称：

  [EN] METAL COMPLEXES HAVING DUAL HISTONE DEACETYLASE INHIBITORY AND DNA-BINDING ACTIVITY
  [FR] COMPLEXES MÉTALLIQUES AYANT UNE DOUBLE ACTIVITÉ INHIBITRICE D'HISTONE DÉSACÉTYLASE ET DE LIAISON À L'ADN

  摘要：

  公开号：

  WO2011006908A3
• 作为产物：
  描述：

  肉桂酸 在 氯磺酸 作用下， 生成 4-Chlorsulfonyl-zimtsaeure
  参考文献：
  名称：

  Stewart, Journal of the Chemical Society, 1922, vol. 121, p. 2558

  摘要：

  DOI：

文献信息

• A Simple, Fast and Chemoselective Method for the Preparation of Arylthiols
  作者：Krishnacharya Akamanchi、Eknath Bellale、Mahesh Chaudhari

  DOI：10.1055/s-0029-1216955

  日期：2009.10

  An efficient and convenient method for the synthesis of arylthiols by reaction of sulfonyl chlorides with triphenylphosphine in toluene is reported.

  报道了一种通过磺酰氯与三苯基膦在甲苯中反应合成芳基硫醇的高效便捷方法。
• Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
  申请人：Watkins J. Clare

  公开号：US20050085515A1

  公开（公告）日：2005-04-21

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q 1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(═O) 2 NR 1 — and —NR 1 S(═O) 2 —; R 1 is a sulfonamido substituent; and, Q 2 is an acid leader group; with the proviso that if J is —S(═O) 2 NR 1 —, then Q 1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  本发明涉及某些活性的碳酰胺酸化合物，其抑制HDAC活性，其化学式为：（I）其中，A是芳基基团；Q1是共价键或芳基领导基团；J是从以下选择的磺酰胺键链：—S（═O）2NR1—和—NR1S（═O）2—；R1是磺酰胺取代基；Q2是酸领导基团；但是，如果J是—S（═O）2NR1—，则Q1是芳基领导基团；以及其药学上可接受的盐、溶剂化物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的制药组合物，以及使用这种化合物和组合物，在体内外抑制HDAC，例如抑制增生状况，如癌症和牛皮癣。
• Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
  申请人：——

  公开号：US20040077726A1

  公开（公告）日：2004-04-22

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S (═O)2NR1— and —NR1S(═O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(═O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  本发明涉及具有以下式子的某些活性碳酸酰化合物，其抑制HDAC活性： （I）A是芳基基团；Q1是共价键或芳基导体基团；J是选择自磺酰胺键的以下链：—S（═O）2NR1—和—NR1S（═O）2—；R1是磺酰胺取代基；Q2是酸导体基团；但是，如果J是—S（═O）2NR1—，则Q1是芳基导体基团；以及其药学上可接受的盐、溶剂化物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这些化合物的制药组合物，以及在体外和体内使用这些化合物和组合物来抑制HDAC，例如抑制增生病症，如癌症和牛皮癣。
• Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
  申请人：Watkins J. Clare

  公开号：US20050143385A1

  公开（公告）日：2005-06-30

  This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: wherein: Cy is independently a cyclyl group; Q 1 is independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J 1 is independently a covalent bond or —C(═;O)—; J 2 is independently —C(═O)— or —S(═O) 2 —; Q 2 is independently an acid leader group; wherein: Cy is independently: C 3-20 carbocyclyl, C 3-20 heterocyclyl, or C 5-20 aryl; and is optionally substituted; Q 1 is independently: a covalent bond; C 1-7 alkylene; or C 1-7 alkylene-X—C 1-7 alkylene, —X—C 1-7 alkylene, or C 1-7 alkylene-X—, wherein X is —O— or —S—; and is optionally substituted; Q 2 is independently: C 4-8 alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or: Q 2 is independently: C 5-20 arylene; C 5-20 arylene-C 1-7 alkylene; C 1-7 alkylene-C 5-20 arylene; or, C 1-7 alkylene-C 5-20 arylene-C 1-7 alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  本发明涉及某些卡巴酸类化合物，其抑制以下式中的HDAC（组蛋白去乙酰化酶）活性：其中：Cy独立地是环烷基团；Q1独立地是共价键或环烷基团；哌嗪-1,4-二基基团可选择性取代；J1独立地是共价键或-C（═;O）-；J2独立地是-C（═O）-或-S（═O）2-；Q2独立地是酸性基团；其中：Cy独立地是C3-20碳环烷基、C3-20杂环烷基或C5-20芳基；并且可选择性取代；Q1独立地是：共价键；C1-7烷基；或C1-7烷基-X-C1-7烷基，-X-C1-7烷基或C1-7烷基-X-，其中X为-O-或-S-；并且可选择性取代；Q2独立地是C4-8烷基；并且可选择性取代；并且具有至少4个原子的骨架长度；或：Q2独立地是C5-20芳基、C5-20芳基-C1-7烷基、C1-7烷基-C5-20芳基或C1-7烷基-C5-20芳基-C1-7烷基；并且可选择性取代；并且具有至少4个原子的骨架长度；或其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式或前药。本发明还涉及包含这样的化合物的制药组合物，以及这样的化合物和组合物的使用，无论是在体外还是体内，以抑制HDAC，并用于治疗由HDAC介导的疾病，如癌症、增殖性疾病、牛皮癣等。
• CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS
  申请人：WATKINS Clare J.

  公开号：US20080269237A1

  公开（公告）日：2008-10-30

  This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula: The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  本发明涉及以下化学式中抑制HDAC（组蛋白去乙酰化酶）活性的某些碳酰胺类化合物：同时，本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物的使用，无论是在体内还是体外，以抑制HDAC，并用于治疗由HDAC介导的疾病，如癌症、增殖性疾病、银屑病等。